Every Form 4 that ZOMEDICA CORP (ZOMDF) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ZOMDF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZOMDF filings page.
Zomedica Corp. reported that COO Blair Anthony K received a grant of options to buy 500,000 shares of Common Stock on August 5, 2026, with an exercise price of $0.09 per share and an expiration date of August 4, 2036. One quarter of the options vest on the first anniversary of the grant date, with the remaining options vesting in equal monthly installments until fully vested on August 4, 2030, leaving a reported holding of 500,000 options after the grant.
Zomedica Corp. granted its General Counsel, Karen DeHaan‑Fullerton, 250,000 options to buy common stock at an exercise price of $0.09 per share, expiring on August 4, 2036. One quarter vests on the first anniversary of grant, then 1/48 vests monthly until fully vested by August 4, 2030, leaving 250,000 options held directly after the grant.
Zomedica Corp. reported that Sr Vice President, Sales Russell Kevin Klass received a grant of 250,000 options to buy Common Stock on August 5, 2026, with a conversion or exercise price of 0.0900 per share and an expiration date of August 4, 2036.
The options vest 25% on the first anniversary of the grant date, then in equal monthly installments until fully vested on August 4, 2030. Following this award, he holds 250,000 options directly.
Zomedica Corp. senior vice president of sales Russell Kevin Klass reported an open-market purchase of 104,000 shares of common stock at $0.103 per share through a spouse account, classified as indirect ownership. A separate holding entry shows he directly owns 6,001,000 common shares after the reported transactions.
Director Johnny D. Powers of Zomedica Corp. reported purchasing a total of 200,000 shares of common stock at $0.1030 per share in three non-derivative transactions described as purchases in open market or private transactions.
After these purchases, he directly holds 4,425,000 shares of Zomedica common stock. The filing indicates these trades were not made under a Rule 10b5-1 trading plan.
Zomedica Corp. reports that Sr. Vice President, Sales, Russell Kevin Klass purchased an aggregate 216,899 shares of common stock, without par value, in three open-market transactions at prices between $0.1050 and $0.1070 per share. Following these purchases, he directly holds 6,001,000 common shares.
Zomedica Corp. director Johnny D. Powers reported open-market purchases of company common stock. He bought a total of 300,000 shares in two transactions, acquiring 200,000 shares at $0.106 per share and 100,000 shares at $0.105 per share. These are direct holdings in non-derivative common stock.
Zomedica Corp. director Johnny D. Powers reported buying a total of 500,000 shares of common stock in open-market transactions. He acquired 391,129 shares at an average price of $0.113 per share and 108,871 shares at $0.112 per share, increasing his direct ownership stake through personal share purchases.
Zomedica Corp. CEO and director Larry C. Heaton II reported an open-market purchase of 250,000 shares of the company’s common stock at $0.11 per share. Following this transaction, his direct ownership increased to 1,250,000 common shares.
Zomedica Corp. (ZOMDF) reported a new equity award to one of its directors. The director received a stock appreciation right covering 1,975,033 underlying common shares at a conversion or exercise price of $0.1 per share in a transaction on 11/17/2025 coded as an acquisition. These rights become exercisable on 11/16/2026 and expire on 11/16/2035. Following this grant, the director beneficially owns 1,975,033 derivative securities directly, all tied to Zomedica common stock.
Zomedica Corp. (ZOMDF) reported an equity award to one of its directors. On 11/17/2025, reporting person Johnny Powers acquired 1,823,107 stock appreciation rights, each linked to one share of Zomedica common stock. The rights have a conversion or exercise price of $0.10 per share, with a vesting or exercisability date of 11/16/2026 and an expiration date of 11/16/2035. Following this grant, Powers beneficially owns 1,823,107 derivative securities directly, giving him economic exposure to the same number of Zomedica common shares if the stock price rises above the exercise price.
Zomedica Corp. (ZOMDF) reported an insider equity award for a company director. The filing shows the grant of a stock appreciation right covering 1,823,107 shares of common stock on 11/17/2025. The right has a conversion or exercise price of $0.10 per share, becomes exercisable on 11/16/2026, and expires on 11/16/2035. Following this transaction, the director beneficially owns 1,823,107 derivative securities, held in direct ownership.
Zomedica Corp. (ZOMDF) reported a change in director equity holdings on a Form 4. On 11/17/2025, a director acquired a stock appreciation right covering 1,823,107 derivative securities at a conversion or exercise price of $0.10 per underlying share. The derivative security is linked to 1,823,107 shares of common stock, becomes exercisable on 11/16/2026, and expires on 11/16/2035. Following this transaction, the director beneficially owns 1,823,107 derivative securities with direct ownership reported.
Zomedica Corp. director reports stock appreciation right grant. A company director filed a Form 4 disclosing the award of a stock appreciation right covering 1,823,107 shares of Zomedica common stock on 11/17/2025. The derivative security has an exercise price of $0.1 per share, becomes exercisable on 11/16/2026, and expires on 11/16/2035. Following this transaction, the director beneficially owns 1,823,107 derivative securities directly, each tied to one share of common stock.
Zomedica Corp. (ZOMDF) reported an insider equity award for director Rodney J. Williams. On 11/17/2025, he received a stock appreciation right covering 1,975,033 derivative securities with a conversion or exercise price of $0.1. The right becomes exercisable on 11/16/2026 and expires on 11/16/2035, and is linked to 1,975,033 shares of common stock. Following this grant, he beneficially owned 1,975,033 derivative securities, held in direct ownership.
Zomedica Corp. (ZOMDF) reported a director transaction involving stock appreciation rights. On 11/17/2025, the director acquired 2,126,959 stock appreciation rights with a conversion or exercise price of $0.1 per right. These rights become exercisable on 11/16/2026 and expire on 11/16/2035. Each right is linked to one share of common stock, so the transaction covers 2,126,959 underlying common shares. Following this grant, the director beneficially owns 2,126,959 derivative securities, held directly.
Zomedica Corp. (ZOMDF) reported an insider purchase on a Form 4. Senior Vice President, Sales, Kevin Klass bought 150,000 shares of common stock on November 13, 2025 at $0.097 per share. Following the transaction, he beneficially owned 5,784,101 shares, held directly.
Zomedica Corp. (ZOMDF) reported an insider purchase on Form 4. Kevin Klass, Sr Vice President, Sales, bought 120,000 shares of common stock on 11/10/2025 at $0.098 per share (transaction code P). Following this trade, he directly holds 5,634,101 shares.
Zomedica Corp. (ZOMDF) disclosed an insider purchase on a Form 4. Kevin Klass, the company’s Sr Vice President, Sales, bought 5,000 shares of common stock on 11/07/2025 at $0.095 per share (Transaction Code P). After this trade, he directly owns 5,514,101 shares.
Zomedica Corp. (ZOMDF) reported a Form 4 showing a purchase by Senior Vice President, Sales, Kevin Klass. On 11/06/2025, he acquired 253,007 shares of common stock at $0.08 per share (transaction code P), held as Direct ownership.
Following this transaction, Mr. Klass beneficially owned 5,509,101 shares of Zomedica common stock.